Nuvectis Pharma Investor Presentation Deck
NXP800 Potential Opportunity in Multiple Cancers
ARID1a is an important mutation that can be used as a patient selection strategy
Indication
Ovarian Cancer
(Clear Cell and Endometrioid)
Endometrial Carcinoma
Cholangiocarcinoma
Urothelial
Hepatocellular
Gastric
Estimated Incidence
NuvectisPharma, Inc.
(US)
4,350
66,200
8,000
75,350
34,000
26,550
ARID1a mutation
prevalence
52.9%
35.6%
17.5%
34.0%
26.7%
24.9%
a. The ARID1a mutation detection assay is a standard part of commercially and clinically available NGS panels.
b. Estimate based on a weighted average of the ARID1a mutation prevalence within the major endometrial histology subtypes.
a
Estimated Number of Patients
with ARID1a protein loss (US)
2,300
23,600 b
1,400
25,600
9,070
6,600
12View entire presentation